rilonacept

Ligand id: 6790

Name: rilonacept

No information available.
Summary of Clinical Use
Currently used in the treatment of cryopyrin-associated periodic syndrome (CAPS). Cryopyrin-associated periodic syndrome includes three previously distinct disorders: Familial cold autoinflammatory syndrome; Muckle-Wells syndrome; and CINCA syndrome, that are now considered to represent a disease continuum, all caused by NLRP3 protein mutations.

EMA approval has been withdrawn.
Mechanism Of Action and Pharmacodynamic Effects
Rilonacept acts primarily as a soluble IL-1β decoy receptor (or 'cytokine trap'). It also binds IL-1a and IL-1ra. This action reduces signalling via the IL-1R resulting in immunosuppression.
External links